title: A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  A multi-centre randomized phase II study of single agent nolatrexed dihydrochloride versus doxorubicin was undertaken in Chinese patients with advanced hepatocellular carcinoma (HCC) to study and compare the clinical efficacy of the two drugs.
  
  
  METHODS
  Fifty-four patients with clinical or histological diagnosis of HCC were randomized in a 2:1 ratio to receive nolatrexed or doxorubicin. Nolatrexed 725 mg/m(2)/day was given by continuous infusion via a central venous device for 5 days and doxorubicin 60 mg/m(2) was given as a rapid intravenous infusion every 3 weeks.
  
  
  RESULTS
  No objective responses were observed in either treatment arm. Two patients in the nolatrexed arm and none in the doxorubicin arm had >50% decline in serum alpha-fetoprotein. The median survival for the patients in the nolatrexed and doxorubicin arms was 139 days and 104 days, respectively. Moderate toxicities including leukopenia, thrombocytopenia, mucositis and skin rash were observed in both treatment arms.
  
  
  CONCLUSIONS
  Nolatrexed and doxorubicin are minimally active in the treatment of advanced HCC. Given the small sample size, no difference is observed between the two drugs.
authors.affiliation: Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China. mok206551@cuhk.eu.hk
authors.forename: T S
authors.initials: TS
authors.lastname: Mok
authors.forename: T W
authors.initials: TW
authors.lastname: Leung
authors.forename: S D
authors.initials: SD
authors.lastname: Lee
authors.forename: Y
authors.initials: Y
authors.lastname: Chao
authors.forename: A T
authors.initials: AT
authors.lastname: Chan
authors.forename: A
authors.initials: A
authors.lastname: Huang
authors.forename: M C
authors.initials: MC
authors.lastname: Lui
authors.forename: W
authors.initials: W
authors.lastname: Yeo
authors.forename: K
authors.initials: K
authors.lastname: Chak
authors.forename: A
authors.initials: A
authors.lastname: Johnston
authors.forename: P
authors.initials: P
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D011799:Quinazolines; D004317:Doxorubicin; C099178:nolatrexed